Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn et al. · Journal of Clinical Oncology · 2020
PURPOSE Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related quality of life (QoL) versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer (NSCLC) at first interim analysis (99 events; median brigatinib follow-up, 11.0 months) in the open-label, phase III ALTA-1L trial (ClinicalTrials.gov identifier: NCT02737501 ). We report results of the second prespecified interim analysis (150 events). METHODS Patients with ALK inhibitor–naive advanced ALK-positive NSCLC were randomly assigned 1:1 to brigatinib 180 mg once daily (7-day lead-in at 90 mg once daily) or crizotinib 250 mg twice daily. The primary end point was PFS as assessed by blinded independent review committee (BIRC). Investigator-assessed efficacy, blood samples for pharmacokinetic assessments, and patient-reported outcomes were also collected. RESULTS Two hundred seventy-five patients were randomly assigned (brigatinib, n = 137; crizotinib, n = 138). With median follow-up of 24.9 months for brigatinib (150 PFS events), brigatinib showed consistent superiority in BIRC-assessed PFS versus crizotinib (hazard ratio [HR], 0.49 [95% CI, 0.35 to 0.68]; log-rank P < .0001; median, 24.0 v 11.0 months). Investigator-assessed PFS HR was 0.43 (95% CI, 0.31 to 0.61; median, 29.4 v 9.2 months). No new safety concerns emerged. Brigatinib delayed median time to worsening of global health status/QoL scores compared with crizotinib (HR, 0.70 [95% CI, 0.49 to 1.00]; log-rank P = .049). Brigatinib daily area under the plasma concentration–time curve was not a predictor of PFS (HR, 1.005 [95% CI, 0.98 to 1.031]; P = .69). CONCLUSION Brigatinib represents a once-daily ALK inhibitor with superior efficacy, tolerability, and QoL over crizotinib, making it a promising first-line treatment of ALK-positive NSCLC.
Cited by 351 works. doi:10.1200/jco.20.00505
Authors
- D. Ross Camidge
- Hye Ryun Kim
- Myung‐Ju Ahn
- James Chih‐Hsin Yang
- Ji‐Youn Han
- Maximilian Johannes Hochmair
- Ki Hyeong Lee
- Angelo Delmonte
- M.R. García Campelo
- Dong‐Wan Kim
- Frank Griesinger
- Enriqueta Felip
- Raffaele Califano
- Alexander I. Spira
- Scott N. Gettinger
- Marcello Tiseo
- Huamao Mark Lin
- Neeraj Gupta
- Michael J. Hanley
- Quanhong Ni
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- Interim analysis: The alpha spending function approach
- The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials
- Constructing Inverse Probability Weights for Marginal Structural Models
- EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
- Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers